阿哌沙班治疗沙特阿拉伯癌症静脉血栓栓塞患者的安全性和有效性的真实世界分析

Lolwa Alabdelmuhsin, Metab F Alwethairi, O. Almadani, Turki A. Althunian, H. Badreldin
{"title":"阿哌沙班治疗沙特阿拉伯癌症静脉血栓栓塞患者的安全性和有效性的真实世界分析","authors":"Lolwa Alabdelmuhsin, Metab F Alwethairi, O. Almadani, Turki A. Althunian, H. Badreldin","doi":"10.3390/jvd2010008","DOIUrl":null,"url":null,"abstract":"Purpose: This study was conducted to evaluate the effectiveness and safety of apixaban in patients with cancer for the treatment of venous thromboembolism (VTE) at a tertiary medical institution in Saudi Arabia. Methods: An observational retrospective cohort study was conducted on adult patients with cancer who were diagnosed with VTE and received apixaban therapy from August 2016 to October 2020. Results: A total of 478 patients were screened; 99 patients were included in the final analysis. Of those included, 38 (38%) were female, 74 (77.1%) had a solid tumor, and 36 (36.4%) were receiving apixaban therapy due to developing proximal deep vein thrombosis (DVT), and the mean age was 58.59 (±14.77). At six months, thrombotic events occurred in 11 patients (11.1%), and bleeding events occurred in 14 (14.1%) of the included individuals. Mortality occurred in 9 (9.09%) of the included individuals. Close to 32% individuals discontinued apixaban therapy at six months. Conclusion: The prevalence of recurrent VTE and bleeding events in patients with cancer using apixaban for treating VTE is in line with many other real-world studies but slightly higher compared to the patients enrolled in the Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (CARAVAGGIO) trial.","PeriodicalId":74009,"journal":{"name":"Journal of vascular diseases","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Analysis of the Safety and Effectiveness of Apixaban Therapy in Cancer Patients with Venous Thromboembolism in Saudi Arabia\",\"authors\":\"Lolwa Alabdelmuhsin, Metab F Alwethairi, O. Almadani, Turki A. Althunian, H. Badreldin\",\"doi\":\"10.3390/jvd2010008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: This study was conducted to evaluate the effectiveness and safety of apixaban in patients with cancer for the treatment of venous thromboembolism (VTE) at a tertiary medical institution in Saudi Arabia. Methods: An observational retrospective cohort study was conducted on adult patients with cancer who were diagnosed with VTE and received apixaban therapy from August 2016 to October 2020. Results: A total of 478 patients were screened; 99 patients were included in the final analysis. Of those included, 38 (38%) were female, 74 (77.1%) had a solid tumor, and 36 (36.4%) were receiving apixaban therapy due to developing proximal deep vein thrombosis (DVT), and the mean age was 58.59 (±14.77). At six months, thrombotic events occurred in 11 patients (11.1%), and bleeding events occurred in 14 (14.1%) of the included individuals. Mortality occurred in 9 (9.09%) of the included individuals. Close to 32% individuals discontinued apixaban therapy at six months. Conclusion: The prevalence of recurrent VTE and bleeding events in patients with cancer using apixaban for treating VTE is in line with many other real-world studies but slightly higher compared to the patients enrolled in the Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (CARAVAGGIO) trial.\",\"PeriodicalId\":74009,\"journal\":{\"name\":\"Journal of vascular diseases\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of vascular diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/jvd2010008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of vascular diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/jvd2010008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在评估阿哌沙班在沙特阿拉伯三级医疗机构治疗静脉血栓栓塞(VTE)的癌症患者中的有效性和安全性。方法:对2016年8月至2020年10月诊断为静脉血栓栓塞并接受阿哌沙班治疗的成年癌症患者进行观察性回顾性队列研究。结果:共筛选478例患者;99例患者纳入最终分析。其中女性38例(38%),患有实体瘤74例(77.1%),因近端深静脉血栓形成(DVT)而接受阿哌沙班治疗36例(36.4%),平均年龄58.59(±14.77)岁。6个月时,11名患者(11.1%)发生血栓形成事件,14名患者(14.1%)发生出血事件。9例(9.09%)死亡。接近32%的个体在6个月时停止阿哌沙班治疗。结论:使用阿哌沙班治疗静脉血栓栓塞的癌症患者复发性静脉血栓栓塞和出血事件的发生率与许多其他现实世界的研究一致,但与阿哌沙班治疗与癌症相关的静脉血栓栓塞(CARAVAGGIO)试验的患者相比略高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-World Analysis of the Safety and Effectiveness of Apixaban Therapy in Cancer Patients with Venous Thromboembolism in Saudi Arabia
Purpose: This study was conducted to evaluate the effectiveness and safety of apixaban in patients with cancer for the treatment of venous thromboembolism (VTE) at a tertiary medical institution in Saudi Arabia. Methods: An observational retrospective cohort study was conducted on adult patients with cancer who were diagnosed with VTE and received apixaban therapy from August 2016 to October 2020. Results: A total of 478 patients were screened; 99 patients were included in the final analysis. Of those included, 38 (38%) were female, 74 (77.1%) had a solid tumor, and 36 (36.4%) were receiving apixaban therapy due to developing proximal deep vein thrombosis (DVT), and the mean age was 58.59 (±14.77). At six months, thrombotic events occurred in 11 patients (11.1%), and bleeding events occurred in 14 (14.1%) of the included individuals. Mortality occurred in 9 (9.09%) of the included individuals. Close to 32% individuals discontinued apixaban therapy at six months. Conclusion: The prevalence of recurrent VTE and bleeding events in patients with cancer using apixaban for treating VTE is in line with many other real-world studies but slightly higher compared to the patients enrolled in the Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (CARAVAGGIO) trial.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信